Scientific deep-dive

Exercise Plus a GLP-1: What Each One Actually Changes

In a four-arm randomized trial, the drug alone produced no improvement in physical fitness. Exercise did, with or without the drug, and the strength result needs reading carefully.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·1 citation

A randomized trial split people who had lost weight by dieting into four groups: exercise, a GLP-1 drug, both, or neither. On physical fitness the answer was unambiguous and not the one the drug’s reputation implies. The drug alone did not improve fitness at all. Exercise did, with or without the drug.[1]

What changed, and in whom

Compared with liraglutide alone, the combined group completed a stair-climb test 1.2 seconds faster (an 8.6% improvement) and improved peak oxygen consumption by 3.0 mL/min per kg of fat-free mass. Exercise alone produced similar benefits. Liraglutide alone produced none.[1]

The exercise was real: a median of 2.65 sessions a week, 116 minutes weekly, at 79% of maximum heart rate. That is structured training rather than walking more, and the trial found no significant difference in how much of it people did whether they were on the drug or on placebo. That answers a common worry about whether these drugs sap the capacity to train. Other training questions, from protein to planning workouts around injection day, are in our exercise Q&A.

The strength result, read carefully

Relative muscle strength (strength normalized to body weight) changed by −7.8% on placebo, −0.4% with exercise, +1.0% with liraglutide and +3.3% with both.[1] It is tempting to read the drug column as the drug making people stronger. It did not.

Relative strength rose because weight fell and absolute strength held. The numerator did not improve; the denominator shrank.

The trial says exactly this: the improvement came from lower weight with preserved absolute strength. That is a good outcome, since carrying the same force through a lighter body is why stairs get easier, but it is not the same claim as building muscle. The distinction is the same one we drew in muscle volume versus muscle function.

Look at the placebo column too. Relative strength fell 7.8% in people who had lost weight by dieting and then did neither exercise nor drug. That is what unsupported weight loss does to functional capacity, and it is the baseline every other arm is being compared against.

Why this trial is so useful

It is directly actionable, and the action is unglamorous. There is no supplement, no peptide, no dose adjustment. The finding is that the drug handles weight and exercise handles fitness, and that they do not substitute for each other. Nor does a sauna substitute for either. Added to exercise in a randomized trial, it improved fitness and blood pressure but not fat loss (see sauna and sweating for weight loss). Metformin goes further the wrong way: in older adults it blunted the fitness and muscle gains from training, covered in metformin vs a GLP-1 for longevity.

  • If fitness matters to you, the drug will not deliver it. Not at the dose tested, on this evidence.
  • Training on a GLP-1 is achievable. Adherence in the drug arm matched the placebo arm at nearly three sessions a week.
  • Exercise beat the drug alone on the functional measures people experience, and on its own it did about as well as the combination.
  • Doing neither, after weight loss, cost 7.8% of relative strength. That is the price of the passive option.

What it does not settle

The trial used liraglutide, a daily older drug, after diet-induced weight loss. Whether semaglutide or tirzepatide behave the same on fitness is untested here, and their larger weight effects could plausibly change the balance in either direction.

It also does not tell you what kind of training is best. Our exercise pairing tool and the strength training cheat sheet cover the practical side, and neither is contradicted by anything here.

Frequently Asked Questions

Not on their own. In a four-arm randomized trial, liraglutide alone produced no improvement in physical fitness, while exercise did, alone or combined with the drug. The combination gave an 8.6% faster stair climb and better peak oxygen consumption than the drug alone, and exercise alone did about as well.
Yes. Participants on the drug completed a median 2.65 sessions a week at 79% of maximum heart rate, with no significant difference from those on placebo. Whatever the drug does to appetite, it did not reduce how much training people did.
No. Relative strength rose 1.0% on the drug, but the trial attributes that to lower body weight with preserved absolute strength, meaning the same force through a lighter body. That is a real functional benefit and it is not muscle building.
Relative muscle strength fell 7.8% in that group. Weight loss without exercise or drug support cost functional capacity, which is the comparison every other arm in the trial is measured against.
Untested here. The trial used liraglutide after diet-induced weight loss. The newer drugs produce larger weight changes, which could shift the balance either way, so this is a reasonable prior rather than a proven transfer.

References

  1. 1.Jensen SBK, Fiorenza M, Juhl CR, et al. Physical Fitness with Exercise and GLP-1 Receptor Agonist Treatment Alone or Combined After Diet-Induced Weight Loss: A Secondary Analysis of a Randomized Controlled Trial in Adults with Obesity Sports Medicine. 2026. PMID: 41579235.

Muscle Loss: Drug Versus Dieting

Across 20 trials in 15,782 people, lean mass made up the same fraction of weight lost on incretin drugs as on dieting (p=0.42). Adding resistance training cut it from about a quarter to 17.5%.

6 min read

Ozempic Butt: What Large Weight Loss Changes in the Buttocks

No trial has measured buttock shape on semaglutide or tirzepatide. What changes is gluteal fat, some gluteal muscle and skin that does not retract, the same as with any large weight loss. What the DXA and MRI data show, what resistance training keeps, and what surgery can do.

11 min read

Lifestyle Plus the Drug

Across 98,261 veterans with type 2 diabetes, taking a GLP-1 and keeping six to eight healthy habits was associated with 43% fewer cardiovascular events than three or fewer habits and no drug. The two figures people will compare cannot be compared.

5 min read

Metformin vs GLP-1 for Longevity: The TAME Trial Has Not Started

No trial shows metformin extends life in people without diabetes. TAME, the metformin aging trial, has no registry record and was still unfunded at last report. Semaglutide has randomized outcome data, but only in people already at high risk.

9 min read

Semaglutide and Peripheral Artery Disease: The Label, the Options and Coverage

STRIDE showed semaglutide 1 mg improved walking distance in type 2 diabetes with PAD, and Novo Nordisk filed for a US label change in 2025. Ozempic's label still lists no PAD use, but PAD already counts as cardiovascular disease on the Ozempic and Wegovy labels.

7 min read

How Far You Can Walk

Peripheral artery disease stops people walking, and almost nothing improves it. A trial of 792 people measured actual walking distance, and the spread matters as much as the median.

6 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.4

Wellorithm

Compounded semaglutide at a flat $247 every 28 days, any dose

8.5

Gala

Moving between compounded and brand without changing seller

7.9

Luvo Health

Moving between compounded and brand without changing seller

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →